Lymphocytes armed to kill: how customised cell engineering advances immunotherapy
The immune system is now regarded as a powerful weapon in the war against cancer, and in the current era immune cells have become ‘living drugs’. This review article considers some of the key advances in immuno-oncology…
The idea that the immune system’s own power can be harnessed and redirected to detect and destroy cancer cells has become a reality in the last decade.
We have come a long way from William Coley’s early suspicions that a link might exist between the immune system and an anti-cancer effect when he first observed that patients with sarcoma experienced tumour regression following severe bacterial infections. Much later, by isolating tumour infiltrating lymphocytes (TILs), a direct relationship between cancer and the immune system was discovered, which permitted a greater understanding of cellular immunology and the molecular mechanisms underlying the immune response to cancer.
This knowledge led to a new therapeutic approach that resulted in many success stories, primarily in the treatment of melanoma.
The rest of this article is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!